================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: January 19, 2004
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
QLT reported today that its alliance partner Novartis Ophthalmics
will offer a temporary discount on Visudyne(R) to physician customers, in
response to a reduction in the Medicare reimbursement rate of Visudyne resulting
from implementation of the Medicare Prescription Drug Improvement and
Modernization Act of 2003. QLT also reported that QLT and Novartis have made a
request to the Centers for Medicare and Medicaid Services requesting an
exception from the reimbursement reduction for Visudyne, in respect of which
they expect a response on April 1, 2004.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press Release dated January 19, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
------------
(Registrant)
Date January 19, 2004 /s/ Paul J. Hastings
----------------------------- -------------------------------------
(Signature)
President and Chief Executive Officer